A phase I safety and pharmacokinetic study of ABT-263 in combination with carboplatin/paclitaxel in the treatment of patients with solid tumors

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 976-984

  Vlahovic, Gordana ^a   Karantza, Vassiliki ^b   Wang, Ding ^c   Cosgrove, David ^d   Rudersdorf, Nikita ^e   Yang, Jianning ^e   Xiong, Hao ^e   Busman, Todd ^e   Mabry, Mack ^e  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b RUTGERS CANCER INSTITUTE OF NEW JERSEY   (United States)

^c Henry Ford Health Science Center   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e ABBVIE INC   (United States)

Author keywords

ABT 263; Carboplatin; Paclitaxel; Phase I

Indexed keywords

ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; CARBOPLATIN; NAVITOCLAX; PACLITAXEL; SULFONAMIDE;

ADULT; AGED; BLOOD; CLINICAL TRIAL; FEMALE; HUMAN; MALE; MIDDLE AGED; NEOPLASMS; PHASE 1 CLINICAL TRIAL; TREATMENT OUTCOME;

ADULT; AGED; ANILINE COMPOUNDS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PACLITAXEL; SULFONAMIDES; TREATMENT OUTCOME;

EID: 84930738714     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0116-3     Document Type: Article

References (25)

1. Moffitt KL, Martin SL, Walker B (2010) From sentencing to execution-the processes of apoptosis. J Pharm Pharmacol 62:547-562
2. Fulda S (2009) Tumor resistance to apoptosis. Int J Cancer 124:511-515
3. Fulda S (2010) Evasion of apoptosis as a cellular stress response in cancer. Int J Cell Biol 2010:370835
4. Del Gaizo MV, Letai A (2008) Rational design of therapeutics targeting the BCL-2 family: are some cancer cells primed for death but waiting for a final push? Adv Exp Med Biol 615:159-175
5. Azmi AS, Mohammad RM (2009) Non-peptidic small molecule inhibitors against Bcl-2 for cancer therapy. J Cell Physiol 218:13-21
6. Kang MH, Reynolds CP (2009) Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 15:1126-1132
7. Leibowitz B, Yu J (2010) Mitochondrial signaling in cell death via the Bcl-2 family. Cancer Biol Ther 9:417-422
8. Tse C, Shoemaker AR, Adickes J et al (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68:3421-3428
9. Gandhi L, Camidge DR, Ribeiro de Oliveira M (2011) Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors. J Clin Oncol 29:909-916
10. Roberts AW, Seymour JF, Brown JR et al (2012) Substantial susceptibility of chronic lymphocytic leukemia to BCL2 inhibition: results of a phase I study of navitoclax in patients with relapsed or refractory disease. J Clin Oncol 30:488-496
11. Rudin CM, Hann CL, Garon EB et al (2012) Phase II study of singleagent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18:3163-3169
12. Wilson WH, O'Connor OA, Czuczman MS et al (2010) Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol 11:1149-1159
13. Ackler S, Mitten MJ, Foster K et al (2010) The Bcl-2 inhibitor ABT-263 enhances the response of multiple chemotherapeutic regimens in hematologic tumors in vivo. Cancer Chemother Pharmacol 66:869-880
14. Belmont L, Tan N, Wong M, et al.: Predicting synergy: Drug combination screening to identify predictive biomarkers for combination drug therapy. Mol Biol Cell 22, 2011
15. Chen J, Jin S, Abraham V et al (2011) The Bcl-2/Bcl-X (L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther 10:2340-2349
16. Sakuma Y, Tsunezumi J, Nakamura Y et al (2011) ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis. Oncol Rep 25:661-667
17. Wong M, Tan N, Kassees R, et al.: Navitoclax enhances the activity of chemo-therapeutic and targeted agents across a large panel of epithelial cancer cell lines. Cancer Res 71, 2011
18. Wong M, Tan N, Zha J et al (2012) Navitoclax (ABT-263) reduces Bcl-x (L)-mediated chemo resistance in ovarian cancer models. Mol Cancer Ther 11:1026-1035
19. Wheate NJ, Walker S, Craig GE et al (2010) The status of platinum anticancer drugs in the clinic and in clinical trials. Dalton Trans 39: 8113-8127
20. Jordan MA, Wilson L (2004) Microtubules as a target for anticancer drugs. Nat Rev Cancer 4:253-265
21. Voss MH, Feldman DR (2011) Paclitaxel, ifosfamide and cisplatin (TIP) beyond its original indication for salvage treatment of germ cell tumors. Onkologie 34:410-411
22. Therasse P, Arbuck SG, Eisenhauer EA et al (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 92:205-216
23. Oken MM, Creech RH, Tormey DC et al (1982) Toxicity and response criteria of the Eastern cooperative oncology group. Am J Clin Oncol 5:649-655
24. National Cancer Institute: Common Terminology Criteria for Adverse Events, Version 3.0, 2006
25. Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-247